Gainers

• Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million.
• InnovAge Holding (NASDAQ:INNV) shares moved upwards by 11.21% to $11.7. The company's market cap stands at $1.4 billion. As per the news, the Q4 earnings report came out yesterday.
• bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 10.75% to $9.89. The market value of their outstanding shares is at $5.3 million.
• Decoy Therapeutics (NASDAQ:DCOY) shares moved upwards by 10.64% to $2.91. The market value of their outstanding shares is at $1.7 million.
• Opus Genetics (NASDAQ:IRD) shares increased by 10.13% to $4.78. The company's market cap stands at $361.0 million.
• Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved upwards by 9.95% to $0.53. The company's market cap stands at $8.9 million.

Losers

• Tyra Biosciences (NASDAQ:TYRA) stock declined by 26.7% to $19.59 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.5 billion.
• Pyxis Oncology (NASDAQ:PYXS) stock declined by 16.97% to $3.23. The company's market cap stands at $324.4 million.
• ENvue Medical (NASDAQ:FEED) stock fell 10.99% to $3.81. The company's market cap stands at $3.9 million.
• Scienture Holdings (NASDAQ:SCNX) stock declined by 10.59% to $0.33. The market value of their outstanding shares is at $14.9 million.
• Evommune (NYSE:EVMN) stock decreased by 10.11% to $11.76. The company's market cap stands at $474.7 million.
• Vivos Therapeutics (NASDAQ:VVOS) stock decreased by 9.52% to $0.16. The market value of their outstanding shares is at $3.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.